Great Lakes Retirement Inc. Has $1.98 Million Stake in Zoetis Inc. $ZTS

Great Lakes Retirement Inc. grew its holdings in Zoetis Inc. (NYSE:ZTS) by 8.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,719 shares of the company’s stock after purchasing an additional 943 shares during the period. Great Lakes Retirement Inc.’s holdings in Zoetis were worth $1,984,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Nova Wealth Management Inc. acquired a new position in Zoetis during the first quarter valued at approximately $25,000. 1248 Management LLC acquired a new position in Zoetis during the first quarter valued at approximately $27,000. Saudi Central Bank acquired a new position in Zoetis during the first quarter valued at approximately $29,000. REAP Financial Group LLC grew its holdings in Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the last quarter. Finally, Cornerstone Planning Group LLC grew its holdings in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on ZTS. UBS Group lowered their price target on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a report on Monday, October 20th. Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Finally, Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average target price of $195.00.

Zoetis Stock Up 0.1%

ZTS opened at $144.25 on Friday. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $183.11. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $63.93 billion, a price-to-earnings ratio of 24.83, a P/E/G ratio of 2.31 and a beta of 0.90. The business has a 50 day moving average of $147.15 and a 200-day moving average of $153.36.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 34.42%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.